Scroll for more

About

 

Locations

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company, headquartered in the United States.

Other Sucampo offices worldwide

SwitzerlandUnited KingdomJapan

 

 

 

United States

Sucampo Pharmaceuticals, Inc.

805 King Farm Boulevard, Suite 550
Rockville, Maryland 20850

Phone: +1-301-961-3400
Fax: +1-301-961-3440
Email: info@sucampo.com

 
 

Learn more about our product in the United States.


 

United Kingdom

Sucampo Pharma Europe, Ltd.

99 Park Drive
Milton Park,
Abingdon, Oxfordshire, OX14 4RY
United Kingdom

 
 

Learn more about our product in the United Kingdom.


 

Switzerland

Sucampo AG

Baarerstrasse 22
6300 Zug
Switzerland

Phone: +41-41-726-30-30
Fax: +41-41-726-30-31
Email: infoeu@sucampo.com

 
 

Learn more about our product in Switzerland.


 

Japan

SUCAMPO PHARMA, LLC

Learn More (English)

Learn More (Japanese)

HEAD OFFICE
1-1-7, Uchisaiwaicho, Chiyoda-ku
Tokyo 100-0011
Japan

Phone: +81-3-3596-8011
Fax: +81-3-3596-8023
Email: sucampopharmallc.info@sucampo.com

 
 

Learn more about our product in Japan.


 

Japan

SUCAMPO PHARMA, LLC

KOBE R&D INSTITUTE
6-7-6, Minatojimaminamimachi, Chuo-ku, Kobe,
Hyogo 650-0047
Japan

Phone: +81-78-599-5340
Fax: +81-78-599-5352
Email: sucampopharmallc.info@sucampo.com

 
 

Learn more about our product in Japan.


 

Japan

SUCAMPO PHARMA, LLC

SANDA FACTORY
4-1, Technopark, Sanda
Hyogo 669-1339
Japan

Phone: +81-79-560-7181
Fax: +81-79-560-7180
Email: sucampopharmallc.info@sucampo.com

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.